Kestenberg-Messina Kaitlin M. 4

What Happened Kaitlin M. Kestenberg-Messina, Chief Operating Officer and SVP, Compliance of ADMA BIOLOGICS, INC. (ADMA), was granted equity awards on February 9, 2026. The Form 4 reports (A) 91,631 restricted stock units (RSUs) and (A, derivative) 144,230 RSUs — both recorded at $0.00 per share (these are compensation awards, not purchases or sales). The awards will convert into common stock upon vesting; no cash changed hands at grant.

Key Details

• Transaction date/filed: February 9, 2026 (reported on Form 4 filed Feb 11, 2026) — filing appears timely.
• Grant details: 91,631 RSUs (new grant) and 144,230 RSUs reported as derivative awards; both show $0.00 per share (compensation grants).
• Shares owned after transaction: 194,166 shares of common stock directly owned. In addition, the filing discloses approximately 386,155 unvested RSUs across multiple grants (including the new 91,631), which vest quarterly over multi-year schedules.
• Vesting notes: The new RSUs vest quarterly on each annual anniversary over four years, subject to continued service (per footnote). Other prior RSU grants listed in the filing also vest quarterly; some prior option grants vest over four years (fully vested by Feb 9, 2030 per footnote).
• Transaction code: A = Award/Grant (derivative classification noted for one grant). No tax-withholding sale or 10b5-1 plan indicated.

Context RSU grants are routine executive compensation and do not represent open-market buying or selling. They become common shares only as they vest (subject to service conditions). For retail investors, awards signal management compensation alignment but are not a direct signal of immediate insider buying/selling behavior.